Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis

European Respiratory Journal

Volumn 42, Issue 2, 2013, Pages 504-512

  Alsaad, Noor ^a   Van Altena, Richard ^a   Pranger, Arianna D ^a   Van Soolingen, Dick ^b,c   De Lange, Wiel C M ^a   Van Der Werf, Tjip S ^a   Kosterink, Jos G W ^a   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; CYCLOSERINE; DOXYCYCLINE; ERTAPENEM; ETHAMBUTOL; IMIPENEM; ISONIAZID; KANAMYCIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TIGECYCLINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; DIARRHEA; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOPENIA; LUNG TUBERCULOSIS; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; STEADY STATE; THROMBOCYTOPENIA; TREATMENT DURATION; UROGENITAL TUBERCULOSIS; VOMITING;

ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84882601099     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00114812     Document Type: Article

References (32)

1. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006; 10: 829-837.
2. Alffenaar JW, van Altena R, Harmelink IM, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet 2010; 49: 559-565.
3. Forgacs P, Wengenack NL, Hall L, et al. Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 2009; 53: 4789-4793.
4. De Angelis DV, Woolley JL, Sigel CW. High-performance liquid chromatographic assay for the simultaneous measurement of trimethoprim and sulfamethoxazole in plasma or urine. Ther Drug Monit 1990; 12: 382-392.
5. Nightingale CH, Ambrose P, File TM Jr, eds. Community Acquired Respiratory Infections. New York, Marcel Dekker, Inc., 2003.
6. Krolicki A, Klimowicz A, Bielecka-Grzela S, et al. Penetration of cotrimoxazole components into skin after a single oral dose. Theoretical versus experimental approach. Pol J Pharmacol 2004; 56: 257-263.
7. Dudley MN, Levitz RE, Quintiliani R, et al. Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. Antimicrob Agents Chemother 1984; 26: 811-814.
8. Chin TW, Vandenbroucke A, Fong IW. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother 1995; 39: 28-33.
9. Ribera E, Pou L, Fernandez-Sola A, et al. Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 3238-3241.
10. Huang TS, Kunin CM, Yan BS, et al. Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a year period in Taiwan. J Antimicrob Chemother 2012; 67: 633-637.
11. Ong W, Sievers A, Leslie DE. Mycobacterium tuberculosis and sulfamethoxazole susceptibility. Antimicrob Agents Chemother 2010; 54: 2748.
12. Cheng AC, McBryde ES, Wuthiekanun V, et al. Dosing regimens of cotrimoxazole (trimethoprimsulfamethoxazole) for melioidosis. Antimicrob Agents Chemother 2009; 53: 4193-4199.
13. Masters PA, O?Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. Arch InternMed 2003; 163: 402-410.
14. Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc 1999; 74: 730-734.
15. Masters PA, O?Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. Arch InternMed 2003; 163: 402-410.
16. Mori H, Kuroda Y, Imamura S, et al. Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. Intern Med 2003; 42: 665-669.
17. Heimpel H, Raghavachar A. Hematological side effects of co-trimoxazole. Infection 1987; 15: Suppl. 5, S248-S253.
18. Nowak A, Klimowicz A, Kadykow M. Distribution of trimethoprim and sulphamethoxazole in blood during treatment with co-trimoxazole. Eur J Clin Pharmacol 1985; 29: 231-234.
19. Wijkstrom A, Westerlund D. Plasma protein binding of sulphadiazine, sulphamethoxazole and trimethoprim determined by ultrafiltration. J Pharm Biomed Anal 1983; 1: 293-299.
20. Proost JH, Eleveld DJ. Performance of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data sets. Pharm Res 2006; 23: 2748-2759.
21. van Klingeren B, Dessens-Kroon M, van der Laan T, et al. Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method. J Clin Microbiol 2007; 45: 2662-2668.
22. Hanses F, Zierhut S, Scholmerich J, et al. Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients - a report of two cases. Int J Infect Dis 2009; 13: e467-e469.
23. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009. www.eortc.be/services/doc/ctc/ CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf Date last updated: June 14, 2010. Date last accessed: May 2012.
24. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
25. Barroso EC, Pinheiro VG, Facanha MC, et al. Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. Am J Trop Med Hyg 2009; 81: 322-329.
26. Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004; 23: 243-255.
27. Balasubramanian V, Solapure S, Gaonkar S, et al. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model. Antimicrob Agents Chemother 2012; 56: 3054-3057.
28. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d?Ivoire: a randomised controlled trial. Lancet 1999; 353: 1469-1475.
29. Nunn AJ, Mwaba P, Chintu C, et al. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ 2008; 337: a257.
30. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46: 2723-2726.
31. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDRTB) - a report of ten cases. J Infect 2006; 52: 92-96.
32. Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-1651.